Asia–Pacific Real-World Evolocumab Use, LDL-C Reduction, Physician Goals, and Patient Perceptions: HALES Observational Study
Real-world, Asia-Pacific data showed that LDL-C reduction after initiating evolocumab was consistent with that observed in other clinical trials and patient populations. Graphical abstract available for this article.·.
Authors
- Surbhi Leekha (ORCID: https://orcid.org/0000-0002-4565-6439)
- Pisit Hutayanon (ORCID: https://orcid.org/0000-0002-6402-6125)
- David Colquhoun (ORCID: https://orcid.org/0000-0002-4263-017X)
- Karam Kostner
- Kamlanathan Kodiappan
- Hung‐Yu Chang (ORCID: https://orcid.org/0000-0003-1219-7739)
- Hung‐Fat Tse (ORCID: https://orcid.org/0000-0002-9578-7808)
- Kian Keong Poh (ORCID: https://orcid.org/0000-0003-3515-7924)
- Myoung-Sun Cho
- Jung‐Sun Kim (ORCID: https://orcid.org/0000-0003-2263-3274)
- Jeff Lange (ORCID: https://orcid.org/0000-0003-4973-2512)
Institutions
- Thammasat University (TH)
- Mater Health Services (AU)
- National Yang Ming Chiao Tung University (TW)
- The University of Queensland (AU)
- National University of Singapore (SG)
- Yonsei University (KR)
- Severance Hospital (KR)
- Greenslopes Private Hospital (AU)
- Wesley Hospital (AU)
- Queen Mary Hospital (CN)
- Seoul Medical Center (KR)
- Cheng Hsin General Hospital (TW)
- Mater Private Hospital (AU)
- National University Health System (SG)
- Mater Adult Hospital (AU)
- University of Hong Kong (HK)
Publication Details
- Journal
- Cardiology and Therapy
- Published
- 2024-10-25
- DOI
- https://doi.org/10.1007/s40119-024-00384-3
- Citations
- 2
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 1.15
Funders
- Amgen
- AstraZeneca